What is Brugada Syndrome? A Cardiac Electrical Disorder Overview

Brugada syndrome is a hereditary cardiac channelopathy, a genetic disorder of the ion channel proteins themselves, in which a structural defect in the cardiac sodium channel causes abnormal electrical repolarization specifically in the right ventricular outflow tract. Rather than producing structural damage to the heart muscle, the condition creates an invisible but potentially lethal electrical instability that can trigger life-threatening ventricular arrhythmias without warning, even in a structurally normal heart.
At our specialized electrophysiology and inherited cardiac conditions clinic, we evaluate Brugada syndrome as a primary electrical disease of the myocardium requiring expert arrhythmia risk stratification, genetic family screening, and individualized long-term management, not a condition that can be assessed or monitored adequately in a general cardiology setting.

To design an accurate diagnostic and risk management plan, Brugada syndrome is classified based on the electrocardiographic pattern observed on the Brugada syndrome ECG, which serves as the central diagnostic tool for identifying this condition:
Type 1 Brugada Pattern: Spontaneous Coved: The only pattern considered definitively diagnostic, characterized by a coved-type ST-segment elevation of 2mm or greater in one or more of the right precordial leads (V1 to V2), followed by a negative T-wave. When this pattern appears spontaneously on a resting ECG in the absence of fever or drug provocation, and is accompanied by clinical features, it establishes the diagnosis of Brugada syndrome.
Type 2 Brugada Pattern: Saddle-Back: A saddle-back ST elevation pattern visible on resting ECG that does not meet diagnostic criteria on its own but warrants sodium channel blocker provocation testing to unmask a concealed Type 1 pattern. This variant is frequently identified during incidental ECG screening.
Concealed Brugada Syndrome: A significant proportion of genetically confirmed carriers display a normal resting ECG between events. In these individuals, the characteristic Brugada syndrome ECG pattern is transiently unmasked by fever, certain medications, alcohol excess, or vagal surges, making the condition entirely invisible to standard screening without specialist provocative testing.

Recognizing the Symptoms of Brugada Syndrome

Recognizing the Symptoms of Brugada Syndrome

Understanding the symptoms of Brugada syndrome is complicated by the condition's characteristically silent natural history between arrhythmic events. Many carriers live for decades without any warning, while others experience their first manifestation as sudden cardiac arrest during sleep or at rest. Recognizing the clinical indicators that prompt specialist referral can be life-saving.

 
The core symptoms of Brugada syndrome and associated warning signs include:

 
Nocturnal Sudden Cardiac Arrest or Resuscitated Ventricular Fibrillation: The most devastating presentation, in which the patient suffers a cardiac arrest, typically during sleep or rest when vagal tone is highest, due to spontaneous degeneration of the cardiac rhythm into ventricular fibrillation. Survival depends entirely on the immediacy of defibrillation, and resuscitated arrest represents the highest-risk category requiring immediate device implantation.

 
Unexplained Syncope: Sudden, transient loss of consciousness without a prodrome of dizziness or nausea, particularly when occurring at rest, during sleep, or after a febrile illness, is a cardinal clinical feature among Brugada syndrome symptoms and must be distinguished from vasovagal syncope through specialist electrophysiological evaluation.

 
Nocturnal Agonal Breathing or Seizure-Like Activity: Family members may witness abnormal nighttime breathing patterns, gasping, or convulsive movements in the affected individual. These presentations represent aborted ventricular arrhythmias rather than primary neurological seizures, and are frequently misattributed to epilepsy before the underlying cardiac diagnosis is established.

 
Palpitations at Rest: Episodes of rapid, irregular heartbeat sensations occurring predominantly during periods of physical inactivity, fever, or after alcohol consumption, reflecting the autonomic and thermal triggers that transiently worsen sodium channel dysfunction in susceptible individuals.

 
Sudden Unexplained Nocturnal Death Syndrome in Family Members: A personal or family history of sudden unexplained death during sleep in a young, apparently healthy individual, particularly in Southeast Asian males, is strongly associated with Brugada syndrome and mandates systematic genetic and electrocardiographic family screening.

 
Genetic, Molecular, and Environmental Causes of Brugada Syndrome:
The transition from a silent genetic variant to a life-threatening arrhythmic event is driven by the intersection of inherited ion channel dysfunction, autonomic nervous system state, and environmental triggers that further suppress sodium channel availability in vulnerable myocardial tissue.

 
Key etiological factors evaluated by our inherited cardiac conditions team include:

 
SCN5A Gene Mutation and Loss-of-Function Sodium Channel Defect: Pathogenic variants in the SCN5A gene, encoding the alpha subunit of the cardiac sodium channel Nav1.5, are identified in approximately 20 to 30 percent of clinically diagnosed cases. These loss-of-function mutations reduce sodium current during the early phase of cardiac depolarization, creating a voltage gradient across the right ventricular wall that predisposes to re-entrant ventricular arrhythmias, which is the molecular mechanism underpinning Brugada syndrome.

 
Additional Channelopathy Gene Variants: Mutations in over twenty additional genes, including CACNA1C, CACNB2, SCN1B, SCN2B, SCN3B, and HCN4, have been identified in Brugada syndrome patients without SCN5A mutations. These genes encode calcium channel subunits, sodium channel accessory proteins, and pacemaker current components that collectively modulate right ventricular electrical stability.

 
Febrile Illness as an Arrhythmic Trigger: Elevated core body temperature directly impairs sodium channel kinetics, accelerating inactivation and reducing peak sodium current. This is a well-documented mechanism by which febrile episodes can unmask the concealed Brugada syndrome ECG pattern and precipitate ventricular fibrillation in previously asymptomatic carriers, particularly in children.

 
Sodium Channel-Blocking Medications: A broad range of commonly prescribed drugs, including certain antiarrhythmics, tricyclic antidepressants, antipsychotics, local anaesthetics, and some anticonvulsants, can pharmacologically reproduce or exacerbate Brugada syndrome ECG changes and provoke arrhythmia in susceptible individuals. A comprehensive drug interaction review is mandatory at every clinical encounter.

 
Autonomic Imbalance and Vagal Predominance: High vagal tone during sleep reduces the protective sympathetic drive that partially compensates for deficient sodium channel function. This nocturnal autonomic state explains the well-established predilection of Brugada syndrome arrhythmias for the sleeping hours and underpins the rationale for isoproterenol infusion as an acute arrhythmia suppression strategy.

Who is at the table?

An accurate diagnosis of Brugada syndrome demands expert interpretation of serial resting electrocardiograms, strategic precordial lead repositioning, and in equivocal cases, controlled pharmacological provocation testing. The Brugada syndrome ECG pattern remains the non-negotiable cornerstone of diagnosis, but its intermittent and dynamic nature requires a systematic multi-stage diagnostic approach.

The foundational diagnostic evaluations deployed at our electrophysiology centre include:
High Precordial Lead ECG with V1 and V2 Repositioned to the Second Intercostal Space: Standard 12-lead ECG is the starting point, but the diagnostic yield is substantially increased by repositioning V1 and V2 to the second or third intercostal space. This technique brings the recording electrodes closer to the right ventricular outflow tract, the anatomical origin of the Brugada ECG signature, and uncovers Type 1 patterns invisible on standard lead placement.

Serial and Ambulatory ECG Monitoring: Because the Brugada syndrome ECG pattern fluctuates over time, a single normal tracing does not exclude the diagnosis. Serial 12-lead ECGs recorded at different times, combined with 24 to 48-hour Holter monitoring, increase the probability of capturing spontaneous pattern expression, particularly during febrile episodes or nocturnal periods of high vagal tone.
Sodium Channel Blocker Provocation Testing with Ajmaline or Flecainide Challenge: In patients with a Type 2 saddle-back pattern or a high clinical suspicion but normal resting ECG, intravenous ajmaline (preferred in Europe) or oral flecainide is administered under continuous ECG monitoring and resuscitation-ready conditions. Pharmacological unmasking of a Type 1 coved pattern constitutes a positive provocation test, supporting the Brugada syndrome diagnosis. This test carries a small but real risk of inducing sustained ventricular arrhythmia and must only be performed in a specialist facility.
Implantable Loop Recorder Insertion: For patients with unexplained syncope in whom the resting and provoked ECG are inconclusive, a subcutaneous cardiac monitor implanted under local anaesthetic provides continuous rhythm documentation for up to three years, capturing the arrhythmic substrate responsible for syncopal events and guiding management decisions.
[Unexplained Syncope / Family History] ➔ [High Precordial ECG and Ajmaline Provocation] ➔ [Brugada Syndrome ECG Pattern Confirmed] ➔ [Risk Stratification and Genetic Screening] ➔ [ICD Implantation / Surveillance Programme]
Genetic Testing, Family Cascade Screening, and Electrophysiological Study
Beyond electrocardiographic evaluation, our inherited cardiac conditions team deploys a comprehensive molecular and functional assessment framework to define individual arrhythmic risk, identify at-risk family members, and guide long-term device and pharmacological management decisions.
Advanced diagnostic protocols encompass:
Comprehensive Cardiac Genetic Panel Sequencing: Next-generation sequencing of the SCN5A gene and an extended panel of Brugada syndrome-associated channelopathy genes, reported against curated variant databases to classify identified variants as pathogenic, likely pathogenic, or a variant of uncertain significance. These findings directly inform family cascade screening eligibility and genetic counselling.
First-Degree Family Cascade Screening: All first-degree relatives of a confirmed Brugada syndrome proband are offered clinical evaluation including high precordial ECG, provocation testing where indicated, and genetic testing when a pathogenic variant has been identified in the index case. This systematic programme is designed to identify asymptomatic carriers before their first arrhythmic event.
Electrophysiological Study with Programmed Ventricular Stimulation: An invasive catheter-based procedure in which controlled electrical stimuli are delivered to the right ventricular endocardium to assess inducibility of ventricular fibrillation. While the prognostic value of this test remains debated in current Brugada syndrome risk stratification guidelines, it is selectively deployed in patients with intermediate risk profiles where the result would materially change the management decision.
Cardiac MRI with Late Gadolinium Enhancement: Advanced tissue characterisation imaging to exclude structural myocardial abnormalities, particularly subtle right ventricular fibrosis or fatty infiltration suggesting arrhythmogenic cardiomyopathy, in patients where the differential diagnosis remains uncertain after standard electrocardiographic evaluation.

• Medical Oncologists: (Chemotherapy/Immunotherapy experts)
• Surgical Oncologists: (Organ-specific surgeons)
• Radiation Oncologists: (Targeted radiation experts)
• Pathologists: (Who analyze the cell type)
• Radiologists: (Who interpret the PET-CT/MRI scans)
• Nuclear Medicine Specialists: (Theranostics experts)
• Geneticists: (DNA profiling experts)

Symptoms and Causes

Medical Oncology: Beyond Standard Chemotherapy

The era of "carpet bombing" the body with toxic chemicals is ending. While traditional chemotherapy is still a powerful tool, Liv Hospital specializes in Smart Medicines.

1. Immunotherapy (Unmasking the Cancer)

Cancer cells are clever; they wear a "mask" that tricks your immune system into thinking they are healthy cells (using checkpoints like PD-L1).

• The Treatment: Immunotherapy drugs (Checkpoint Inhibitors) rip this mask off. They do not kill the cancer directly; they unleash your body's own T-cells to identify and attack the tumor.
• The Result: Often fewer side effects than chemo and potentially durable, long-term remission.

2. Targeted Therapy (Smart Drugs)

• The Science: We perform Next-Generation Sequencing (NGS) on your tumor biopsy to find specific genetic mutations (like EGFR, ALK, or BRAF).
• The Treatment: We use oral pills or IV drugs designed to attack only cells with that specific mutation, leaving healthy cells alone. It is like a sniper shot compared to a shotgun blast.

Understanding Cancer and How It Affects the Body

Cancer can affect the body by pressing on organs, which may cause pain or even organ problems. Treatments like chemotherapy target fast-growing cells, so they attack cancer but can also affect healthy cells, leading to side effects like hair loss, tiredness, or nausea. Immunotherapy works by boosting the immune system, which can sometimes cause symptoms similar to the flu.

Radiation Oncology

Diagnosis and Staging

MR-Linac (Unity): Seeing While Treating

Traditional radiation machines use old X-ray images. But tumors move—your lung tumor moves when you breathe; your prostate moves when your bladder fills.

• The Revolution: MR-Linac combines a high-strength MRI machine with a Linear Accelerator.
• The Benefit: We can see the tumor in real-time, crystal-clear definition during the treatment. If the tumor shifts 2mm, the machine pauses or adjusts. This allows us to deliver massive, curative doses (SBRT) in fewer sessions (e.g., 5 days instead of 6 weeks) with minimal side effects.

CyberKnife & Gamma Knife

For brain tumors or spinal metastases, we use Radiosurgery. This is non-invasive "surgery" using radiation beams so precise (sub-millimeter accuracy) that no incision is needed.

Treatment Details

Da Vinci Xi Robotic Surgery

Liv Hospital utilizes the latest robotic systems for complex cancer surgeries:

• Prostate Cancer: Protecting the nerves responsible for potency and urinary control.
• Colorectal Cancer: Removing tumors with tiny incisions, allowing for faster return of bowel function.
• Gynecologic Cancer: Hysterectomies performed with extreme precision.
• The Benefit: The robot provides 3D high-definition vision and wrist movements that human hands cannot perform. This means less blood loss, less pain, and a faster discharge—crucial for international patients who need to fly home.

Nuclear Medicine: Theranostics

We are pioneers in Theranostics (Therapy + Diagnostics). This involves finding cancer cells with a radioactive tracer (PET-CT) and then destroying them with a radioactive missile.

• Lutetium-177: Used for advanced Prostate Cancer (PSMA therapy) and Neuroendocrine Tumors. It seeks out cancer cells throughout the body and delivers radiation directly to them, sparing healthy tissue.

Why Choose Liv Hospital for Cancer Care?

Traveling for cancer treatment is a major decision. Here is why patients from 50+ countries trust Liv Hospital:

1. Speed is Survival: In many countries (UK, Canada), waiting lists for PET-CT scans or surgery can be months long. Cancer does not wait. At Liv Hospital, we typically complete all diagnostics in 3 days and start treatment immediately.
2. JCI Accreditation: We are an accredited Center of Excellence, adhering to strict American safety protocols for chemotherapy preparation and surgical sterility.
3. Comprehensive Support: We treat the person, not just the disease. Our Supportive Care Unit includes:
   • Psycho-Oncology: Psychologists to help navigate the anxiety and depression often associated with diagnosis.
   • Onco-Nutrition: Dietitians to maintain your strength and weight during treatment.
   • Algology (Pain Management): Specialists dedicated to ensuring you are pain-free.
4. Access to Clinical Trials: As a university hospital, we participate in global clinical trials, giving patients access to new drugs before they are widely available.